Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.
about
CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activityCCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in micePlerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsHematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceIdentification of a New Cell Population Constitutively Circulating in Healthy Conditions and Endowed with a Homing Ability Toward Injured Sites.Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution.Peripheral blood stem cell mobilization tactics.Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.Mobilization of hematopoietic stem cells into the peripheral blood.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Advances in stem cell mobilization.The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoCost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
P2860
Q28587353-A29B37C7-EA52-493F-8F87-601C04C39374Q28591940-207AA436-7CEE-457E-B82F-9B8FB5D9683EQ33543723-F6289FA5-3D36-4AD3-919C-A2848B8FC9D1Q34114055-A9AAB4F6-42A3-45E9-9FF7-5535C357FBD5Q34454624-38F12AD8-6CCF-4081-9387-0F6F0313C43FQ34762492-4C2B5935-11EA-45A5-8B65-EEA3745B7889Q36272758-1DFED520-D054-4A5E-8201-71BFC4BA8916Q36445393-7703343A-3B19-4823-9F91-7710561A1E98Q37559470-23B0AEAB-0242-4EC3-8583-312DCF8BA4B2Q37641380-0F67E035-BD7A-41B5-83D0-D4620ABD2C3AQ37649251-2F27DBFE-A8A3-4625-A9E5-D325BDD55A90Q37785509-FFFCFE98-9723-46B8-8132-253B0B63CE15Q37810088-EEC53EF0-4EAC-4CA4-B6FB-5295B0B68E57Q37921284-561FA3D2-47B1-4B85-AF4A-96A497B92206Q38023761-67FF8C30-E8D1-4AA5-B165-56E50E00E5AEQ38037185-BB981512-6A2B-4257-86F0-B49439166553Q38077807-606E100C-A325-44F2-9DA8-05450EB6DCB3Q38183225-D3E92F37-D7D7-443E-978F-57BBD01D0475Q39049318-490F7C7C-F48D-4582-9CB0-100E2880577BQ39724267-2AC1A9A7-0F2A-4D1D-A5ED-A70240A04672Q41003137-3D80E21C-62A0-4171-88C1-E0665977D701Q42592824-ABF3BBE9-A6B5-41DD-8737-5D58D9530B95Q44736591-F669AB18-2D24-4522-BF83-2110E837AF74Q45000707-0E3FBFB8-6998-456C-9E20-5869BCD53EEDQ45892382-CC6D3C07-3FC2-48F0-94C1-0E2E6A10524BQ45964946-684164AA-285A-4C82-BABC-88D9A441D442Q53508311-4D45A589-8287-43D0-8E59-11F4816B70FFQ54582789-4DF7F13E-6631-44C0-B180-793D95A7BFB3
P2860
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Rescue from failed growth fact ...... : an institutional experience.
@en
Rescue from failed growth fact ...... tion with G-CSF and plerixafor
@nl
type
label
Rescue from failed growth fact ...... : an institutional experience.
@en
Rescue from failed growth fact ...... tion with G-CSF and plerixafor
@nl
prefLabel
Rescue from failed growth fact ...... : an institutional experience.
@en
Rescue from failed growth fact ...... tion with G-CSF and plerixafor
@nl
P2093
P2860
P356
P1476
Rescue from failed growth fact ...... : an institutional experience.
@en
P2093
B Hayes-Lattin
G Calandra
R T Maziarz
T Kovacsovics
P2860
P2888
P304
P356
10.1038/BMT.2008.409
P407
P577
2009-02-02T00:00:00Z
P5875
P6179
1024209668